BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37479967)

  • 1. Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making.
    Chitrangi S; Vaity P; Jamdar A; Bhatt S
    BMC Cancer; 2023 Jul; 23(1):689. PubMed ID: 37479967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
    Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
    de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
    Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived organoid culture in epithelial ovarian cancers-Techniques, applications, and future perspectives.
    Chan WS; Mo X; Ip PPC; Tse KY
    Cancer Med; 2023 Oct; 12(19):19714-19731. PubMed ID: 37776168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.
    Chen Y; Liu Y; Chen S; Zhang L; Rao J; Lu X; Ma Y
    Front Immunol; 2023; 14():1180184. PubMed ID: 37334366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
    Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
    Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
    Nero C; Vizzielli G; Lorusso D; Cesari E; Daniele G; Loverro M; Scambia G; Sette C
    J Exp Clin Cancer Res; 2021 Mar; 40(1):116. PubMed ID: 33789687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine.
    Spagnol G; Sensi F; De Tommasi O; Marchetti M; Bonaldo G; Xhindoli L; Noventa M; Agostini M; Tozzi R; Saccardi C
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
    Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.
    Thorel L; Morice PM; Paysant H; Florent R; Babin G; Thomine C; Perréard M; Abeilard E; Giffard F; Brotin E; Denoyelle C; Villenet C; Sebda S; Briand M; Joly F; Dolivet E; Goux D; Blanc-Fournier C; Jeanne C; Villedieu M; Meryet-Figuiere M; Figeac M; Poulain L; Weiswald LB
    J Exp Clin Cancer Res; 2023 Oct; 42(1):260. PubMed ID: 37803448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer.
    Chen P; Zhang X; Ding R; Yang L; Lyu X; Zeng J; Lei JH; Wang L; Bi J; Shao N; Shu D; Wu B; Wu J; Yang Z; Wang H; Wang B; Xiong K; Lu Y; Fu S; Choi TK; Lon NW; Zhang A; Tang D; Quan Y; Meng Y; Miao K; Sun H; Zhao M; Bao J; Zhang L; Xu X; Shi Y; Lin Y; Deng C
    Adv Sci (Weinh); 2021 Nov; 8(22):e2101176. PubMed ID: 34605222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers.
    Thorel L; Divoux J; Lequesne J; Babin G; Morice PM; Florent R; Desmartin G; Lecouflet L; Marde Alagama C; Leconte A; Clarisse B; Briand M; Rouzier R; Gaichies L; Martin-Françoise S; Le Brun JF; Denoyelle C; Vigneron N; Jeanne C; Blanc-Fournier C; Leman R; Vaur D; Figeac M; Meryet-Figuiere M; Joly F; Weiswald LB; Poulain L; Dolivet E
    BMC Cancer; 2024 Jun; 24(1):701. PubMed ID: 38849726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids.
    Graham O; Rodriguez J; van Biljon L; Fashemi B; Graham E; Fuh K; Khabele D; Mullen M
    J Vis Exp; 2023 Jan; (191):. PubMed ID: 36688549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients.
    Choi W; Kim YH; Woo SM; Yu Y; Lee MR; Lee WJ; Chun JW; Sim SH; Chae H; Shim H; Lee KS; Kong SY
    Cancer Res Treat; 2023 Oct; 55(4):1077-1086. PubMed ID: 37309112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform.
    Pan B; Zhao D; Liu Y; Li N; Song C; Li N; Li X; Zhao Z
    In Vitro Cell Dev Biol Anim; 2021 May; 57(5):510-518. PubMed ID: 33950403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived organoids in ovarian cancer: Current research and its clinical relevance.
    Kumar S; Raina M; Tankay K; Ingle GM
    Biochem Pharmacol; 2023 Jul; 213():115589. PubMed ID: 37196684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    Tao M; Wu X
    J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment.
    Cui Y; Ran R; Da Y; Zhang H; Jiang M; Qi X; Zhang W; Niu L; Zhou Y; Zhou C; Tang X; Wang K; Yan Y; Ren Y; Dong D; Zhou Y; Wang H; Gong J; Hu F; Zhao S; Zhang H; Zhang C; Yang J
    J Cell Mol Med; 2024 May; 28(9):e18374. PubMed ID: 38722288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging Prospects for the Study of Colorectal Cancer Stem Cells using Patient-derived Organoids.
    Ding L; Yang Y; Lu Q; Cao Z; Weygant N
    Curr Cancer Drug Targets; 2022; 22(3):195-208. PubMed ID: 35078398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.